Biogen gains fast-track Alzheimer’s drug review in wake of early data
After releasing early data just a day ago that grabbed international headlines, now Biogen ($BIIB) has disclosed that its aducanumab to treat Alzheimer’s disease has
After releasing early data just a day ago that grabbed international headlines, now Biogen ($BIIB) has disclosed that its aducanumab to treat Alzheimer’s disease has